Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  CytoTools AG    T5O   DE000A0KFRJ1

Real-time Quote. Real-time Tradegate - 07/25 08:03:31 am
11.025 EUR   +1.85%
04/27 CYTOTOOLS : DermaTools signs contracts for production by a new Germa..
02/03 CYTOTOOLS : strenghthens DermaTools Biotech GmbH with a  capital inc..
2015 CYTOTOOLS : DermaPro retains its potential
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
07/18/2016 07/19/2016 07/20/2016 07/21/2016 07/22/2016 Date
11.3(c) 11.02(c) 10.99(c) 11.08(c) 10.825(c) Last
4 231 4 685 671 5 331 2 135 Volume
+4.39% -2.48% -0.27% +0.82% -2.30% Change
More quotes
Financials (€)
Sales 2015 1,50 M
EBIT 2015 -2,60 M
Net income 2015 -2,60 M
Finance 2015 0,20 M
Yield 2015 -
Sales 2016 2,60 M
EBIT 2016 -1,30 M
Net income 2016 -1,30 M
Debt 2016 0,50 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales2015 14,3x
EV / Sales2016 8,52x
Capitalization 21,7 M
More Financials
Company
CytoTools AG operates as a biotechnology company, which engages in developing therapeutic from research on programmed death cell.The company was founded by Dirk Kaiser and Mark-Andre Freyberg in 2000 and is headquartered in Darmstadt, Germany. 
Sector
Biotechnology & Medical Research
Calendar
08/29 | 10:00amShareholder meeting
More about the company
Latest news on CYTOTOOLS AG
05/23 DGAP-NEWS : CytoTools AG: Resultate aus der Phase II/III Studie zur Behandlung d..
04/27 CYTOTOOLS : DermaTools signs contracts for production by a new German manufactur..
04/22 DGAP-NEWS : DermaTools Biotech GmbH identifiziert neuen Hersteller für Wirkstoff..
02/03 CYTOTOOLS : strenghthens DermaTools Biotech GmbH with a  capital increase
02/03 CYTOTOOLS : stärkt das Tochterunternehmen DermaTools Biotech GmbH durch Kapitale..
01/26 CYTOTOOLS : klärt die Ursachen der zu geringen Wirkstoffkonzentration auf, die z..
2015 CYTOTOOLS : DermaPro retains its potential
2015 CYTOTOOLS : berichtet: Der Wirkstoff DermaPro(R) behält sein Potential (DGAP New..
2015 CYTOTOOLS : berichtet über Ergebnisse der europäischen klinischen Studie Phase I..
2015 CYTOTOOLS : before important milestones
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Bio Therapeutic Drugs
Advertisement
Chart CYTOTOOLS AG
Duration : Period :
CytoTools AG Technical Analysis Chart | T5O | DE000A0KFRJ1 | 4-Traders
Full-screen chart
Technical analysis trends CYTOTOOLS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 5,50 €
Spread / Average Target -49%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark-Andre Freyberg CEO & Head-Investor Relations
Manfred May Chairman-Supervisory Board
Dirk Kaiser Chief Research Officer
Markus H. Weissbach Chief Medical Officer
Dieter Tober Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOTOOLS AG5.00%24
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
CELGENE CORPORATION-10.22%83 285
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
More Results